Acta Medica Iranica 2017. 55(3):150-165.

Personalized Medicine: Pharmacogenomics and Drug Development
Somayeh Mirsadeghi, Bagher Larijani

Abstract


Personalized medicine aims is to supply the proper drug to the proper patient within the right dose. Pharmacogenomics (PGx) is to recognize genetic variants that may influence drug efficacy and toxicity. All things considered, the fields cover a wide area, including basic drug discovery researches, the genetic origin of pharmacokinetics and pharmacodynamics, novel drug improvement, patient genetic assessment and clinical patient administration. At last, the objective of Pharmacogenomics is to anticipate a patient’s genetic response to a particular drug as a way of presenting the best possible medical treatment. By predicting the drug response of an individual, it will be possible to increase the success of therapies and decrease the incidence of adverse side effect.


Keywords


Personalized medicine; Pharmacogenetics; Drug discovery; Drug safety

Full Text:

PDF

References


Lee VH. Personalized medicine: transforming drug development and healthcare. Ther Deliv 2010;1:615-9.

Cavalli-Sforza LL. The Human Genome Diversity Project: past, present and future. Nat Rev Genet 2005;6:333-40.

Kandpal R, Saviola B, Felton J. The era of 'omics unlimited. Biotechniques 2009;46:351-2.

Guttmacher AE, Collins FS. Realizing the promise of genomics in biomedical research. JAMA 2005;294:1399-402.

Weinshilboum RM. The therapeutic revolution. Clin Pharmacol Ther 1987;42:481-4.

Weinshilboum RM, Wang L. Pharmacogenetics and Pharmacogenomics:Development, Science, and Translation. Ann Rev Genomics Hum Genet 2006;7:223-45.

Vesell ES, Page JG. Genetic control of drug levels in man: antipyrine. Science 1968;161:72-3.

Vesell ES, Page JG. Genetic control of dicumarol levels in man. J Clin Invest 1968;47:2657-63.

Frueh F. Pharmacogenomics. Am J Hum Genet 2003;72:220-1.

Brunton L, Chabner B, Knollman B, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw Hill, 2001:1392-3.

Trusheim MR, Aitken M, Berndt ER. Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules? Forum Health Econ Policy 2010;13:16014.

Wang L. Pharmacogenomics: a systems approach. Wiley Interdiscip Rev Syst Biol Med 2010;2:3-22.

D'Alessandro A, Zolla L. Pharmacoproteomics: a chess game on a protein field. Drug Discov Today 2010;15:1015-23.

Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002;24:46-54.

Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.

Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012;30:1422-8.

Phillips KA, Van Bebbe S, Issa AM, Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov 2006:5:463-9.

Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, et al. The impact of CYP2D6- predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer 2010;103:765-71.

Kramer JA, Sagartz JE, Morris DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007;6:636-49.

Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 1989;41:535-52.

Davis JC, Furstenthal L, Desai AA, Norris T, Sutaria S, Fleming E, et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat Rev Drug Discov 2009;8:279-86.

Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.

Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998;8:283-9.

Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.

Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9-39.

McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001;41:101-21.

Wang L, Weinshilboum R. Thiopurine S- methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006;25:1629-38.

Kalow W. The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture. Pharmacogenetics: past and future. Life Sci 1990;47:1385-97.

Roden DM, Tyndale RF. Pharmacogenomics at the Tipping Point: Challenges and Opportunities. Clin Pharmacol Ther 2011;89:323-7.

Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, et al. Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use. Pharmacotherapy 2008;28:992-8.

Lesko LJ, Zineh L. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics 2010;11:507-12.

Yan SK, Liu RH, Jin HZ, Liu XR, Ye J, Shan L, et al. “Omics” in pharmaceutical research: overview, applications, challenges, and future perspectives. Chin J Nat Med 2015;13:3-21.

Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006;440:1073-7.

Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med;7:201-4.

Ovarian cancer research results from the 2. Prostate, L., Colorectal and Ovarian (PLCO) Cancer Screening Trial: fact sheet. Bethesda, MD: National Cancer Institute. (Accessed December 2016,11,at http://www.cancer.gov/cancertopics/cancertopics/factshee t/ detection/plco-ovarian).

Secretary’s Advisory Committee on Genetics, H., and Society. U.S. system of oversight of genetic testing: a response to the charge of the Secretary of Health and Human Services. Bethesda, MD: National Institutes of Health, 2008. (Accessed December 2016, 11, at http://oba.od.nih.gov/oba/SACGHS/reports/ SACGHS_ oversight_report.pdf).

Secretary’s Advisory Committee on Genetic Testing. Enhancing the oversight of genetic tests: recommendations of the SACGT. Bethesda, M.N.I.o.H., 2000. (Accessed December 2016, 11, at http://oba.od.nih.gov/oba/sacgt/reports/oversight_ report.pdf).

Genetic Testing Registry. Bethesda, M.N.C.f.B., National Library of Medicine; 2010. (Accessed December 2016, 11, at http://www.ncbi.nlm.nih.gov/gtr).

Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001;19:491-6.

Malakoff D Service RF. Genomania Meets the Bottom Line. Science 2001;291:1193-203.

Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige M, et al. Monitoring serum insulin-like growth

factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF- I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol (Oxf) 2000;53:329-36.

Miller MC, 3rd, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 2001;120:269-80.Toxicol Lett 2001;120:269-80.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.